figures. Baseline characteristics of participants included in the final analysis were similar to all randomly assigned participants. In the 194 participants who did not receive an endoscopy, characteristics such as age or severity of adenoma at baseline, that may have affected the likelihood of a follow up, did not differ significantly at baseline. Bonelli et No further Each centre received a Double blinded States that the trial was All drop outs reported: Apparently free of Power al. information random list where the but no further double blinded but no intervention (n=36): refused selective outcome calculations (2012)21 provided than assigned treatment was information further information about follow up colonoscopy reporting - all stated provided but randomization indicated by the label blinding of personnel was (n=29), died (n=6), cancer outcomes reported. required sample lists stratified numbers of the bottles provided. (n=1); control (n=45): size not met. No by centre were containing the pills with no refused follow up collection of provided by reference to their contents. colonoscopy (n=35), died information on the The active compound and the (n=9), cancer (n=1). confounding pharmaceutical placebo had an identical factors at company. appearance and that the baseline. bottles and pills contained no reference to their contents. Limburg "Dynamic No information provided. Some No information provided. Low drop-out rate and drop Apparently free of Power et al. allocation interventions out reasons provided: lost selective outcome calculations (2011)23 procedure". were delivered to follow up (n=3), reporting - all stated provided but as tablets and withdrew consent (n=2), outcomes reported. required sample some as powder. medical contraindications size not met. Also different (n=1), other (n=2). dosages used.
figures. Baseline characteristics of participants included in the final analysis were similar to all randomly assigned participants. In the 194 participants who did not receive an endoscopy, characteristics such as age or severity of adenoma at baseline, that may have affected the likelihood of a follow up, did not differ significantly at baseline. Bonelli et al. (2012)21 No further information provided than randomization lists stratified by centre were provided by the pharmaceutical company. Each centre received a random list where the assigned treatment was indicated by the label numbers of the bottles containing the pills with no reference to their contents. The active compound and the placebo had an identical appearance and that the bottles and pills contained no reference to their contents. Double blinded but no further information States that the trial was double blinded but no further information about blinding of personnel was provided. All drop outs reported: intervention (n=36): refused follow up colonoscopy (n=29), died (n=6), cancer (n=1); control (n=45): refused follow up colonoscopy (n=35), died (n=9), cancer (n=1). Apparently free of selective outcome reporting - all stated outcomes reported. Power calculations provided but required sample size not met. No collection of information on confounding factors at baseline. Limburg et al. (2011)23 "Dynamic allocation procedure". No information provided. Some interventions were delivered as tablets and some as powder. Also different dosages used. No information provided. Low drop-out rate and drop out reasons provided: lost to follow up (n=3), withdrew consent (n=2), medical contraindications (n=1), other (n=2). Apparently free of selective outcome reporting - all stated outcomes reported. Power calculations provided but required sample size not met.
Paper_systematic_review_diet_int_CRC_survivors_with_amendments_FINAL_CLEAN_VERSION2_incl_tables.docx